# Medical Question & Answer

**Sample ID**: 06f23859-369c-464a-ac8f-3e81f298aceb
**Dataset Index**: 798

---

## Question

quick side effecrts amitriptyline for migraine ppx

---

## Answer

> Let's see… What do we have here? The user is asking for the quick side effects of amitriptyline when used for migraine prophylaxis. Let's break this down step-by-step. First, I need to think about the most common adverse effects at preventive doses and how often they occur. Then, I should verify these against high-quality sources like randomized trials and FDA labeling. Next, I will categorize side effects by frequency and clinical relevance, check for dose–response and discontinuation signals, and finally consider special populations and monitoring so the guidance is practical and safe to apply.

> Let me first confirm the dosing and context so I don't overstate risks outside the prophylaxis range. In migraine prevention, amitriptyline is typically used at low doses such as 10–25 mg at bedtime and often titrated toward 25–50 mg if tolerated, with a pivotal trial directly testing 25 mg and demonstrating efficacy, which is the right frame for understanding tolerability here [^116dR2Wc]. I should also confirm that U.S. primary care guidance continues to include amitriptyline among initial options for episodic migraine prevention in nonpregnant adults, which it does, though newer options exist if it is not tolerated [^114wvNRq] [^111vLknW].

> Now, what are the quick, common side effects at these doses? Wait, let me verify with the head-to-head randomized trial and labeling so I list what patients actually report. In the 12-week RCT, the most frequent adverse effects with amitriptyline 25 mg were daytime sleepiness or drowsiness, dry mouth, constipation, epigastric discomfort, and weight gain, with significantly more adverse events versus melatonin and placebo and no serious adverse events observed at this dose, which aligns with clinical experience of anticholinergic and sedating effects at low doses [^1178b2Ap] [^1142sqRR]. The FDA labeling for the amitriptyline-containing product likewise lists drowsiness, dry mouth, constipation, blurred vision, dizziness, and bloating among the most frequently reported symptoms, which corroborates the RCT profile in routine terms patients recognize [^112KqeDe].

> Hold on, orthostatic hypotension is sometimes underappreciated at preventive doses; I should double-check its frequency. The FDA SPL lists orthostatic hypotension among very common adverse reactions to amitriptyline, indicating that even at lower doses, positional lightheadedness can occur and warrants counseling, especially in older adults or those on antihypertensives [^114bjYhF]. But wait, the RCT reported no change in blood pressure between groups, which likely reflects mean seated measures rather than formal orthostatic testing, so I should not dismiss orthostasis risk based on that trial alone when labeling signals are strong [^1178b2Ap] [^114bjYhF].

> I will now examine weight changes and metabolic signals since they often drive discontinuation. Let me verify the magnitude. In the RCT, mean weight gain with 25 mg over three months was approximately 1.0 kg, significantly greater than placebo and opposite in direction to melatonin, which was associated with slight loss, and this effect can appear even at "low" prophylactic doses [^1178b2Ap] [^113HvkKM]. Supporting data suggest amitriptyline can increase leptin and promote weight gain over 12 weeks in migraine populations, which helps explain why early counseling on diet and activity is prudent [^1156ZAwU].

> Next, I should review other common but less specific complaints so I don't omit practical issues. Fatigue and somnolence often overlap and were reported as frequent in comparative contexts, along with dizziness and blurred vision, consistent with antihistaminic and anticholinergic effects at these doses, while epigastralgia or abdominal discomfort also occurred in the trial and can be mitigated by taking the dose at night [^11659CuF] [^1178b2Ap] [^112KqeDe]. But wait, what about cognitive effects and sleep phenomena? Vivid dreams, confusion, and tremor are listed on labeling and may emerge idiosyncratically, so I should remind myself to screen for these if patients report unusual neuropsychiatric symptoms after initiation [^112KqeDe].

> I need to ensure I do not miss rare but clinically serious risks that warrant baseline precautions. Cardiac conduction abnormalities and arrhythmias, including tachycardia, heart block, and even infarction or stroke, have been reported with amitriptyline-class agents and are particularly relevant in patients with known cardiac disease, so a careful cardiac history and consideration of baseline ECG in at-risk patients is advisable before titration even at preventive doses [^112KqeDe]. Hepatic dysfunction and hematologic abnormalities such as jaundice and granulocytopenia are rare but reported; for prolonged therapy, periodic labs can be considered if clinical suspicion arises, and any jaundice or unexplained infection risk should prompt evaluation and discontinuation [^112KqeDe]. I should also confirm pediatric cautions: there is a boxed warning for increased risk of suicidal ideation with antidepressants in children and adolescents; when amitriptyline is considered in youth, families must be counseled and monitored closely, typically alongside CBT when used, but for adults this warning is not the primary constraint for migraine prophylaxis [^116wsq5D].

> Let me reconsider tolerability in context of discontinuation so expectations are clear. In the RCT, adverse events were the most common reason for premature withdrawal across groups, and amitriptyline produced significantly more adverse events than melatonin and placebo, yet no serious adverse events were observed at 25 mg and most events were mild to moderate, suggesting that slow titration and nighttime dosing can improve adherence if patients are prepared for drowsiness and dry mouth early on [^116dR2Wc] [^1178b2Ap] [^1142sqRR]. Hold on, let's not jump to conclusions about population blood pressure neutrality translating to individual safety; individualized orthostatic precautions still apply, especially in older adults, those with autonomic symptoms, or polypharmacy [^114bjYhF] [^1178b2Ap].

> I should confirm the dose–response relationship so I do not overgeneralize from 25 mg. Although some studies of higher daily means around 75 mg found comparable efficacy to topiramate, they also reported higher rates of anticholinergic and sedative adverse events that would likely raise dropout rates in typical migraine clinics, reinforcing the practical approach of starting low and titrating cautiously while balancing benefit and tolerability at 25–50 mg when possible [^11659CuF]. The trial choice of 25 mg reflects a common clinical practice point for migraine prophylaxis, supporting that most of the side effect burden relevant to "quick" counseling will already be evident at this dose range [^1142sqRR].

> Before I summarize, I need to check special situations. In older adults, the combination of anticholinergic load, sedation, and orthostatic hypotension increases fall risk, so lower starting doses and slower titration with explicit orthostatic precautions are prudent, particularly when other sedatives or antihypertensives are on board [^114bjYhF]. In patients with cardiovascular disease or conduction abnormalities, baseline assessment and avoidance or specialist co-management are reasonable given labeling signals for arrhythmia risk, even though serious events are uncommon at low doses in otherwise healthy adults [^112KqeDe]. In pregnancy, preventive pharmacotherapy should generally be avoided when possible and nonpharmacologic strategies emphasized, so amitriptyline is usually deferred unless the benefits clearly outweigh risks after multidisciplinary discussion [^1147fHrh].

> Bottom line quick list, keeping it practical and evidence-tied: very common/common at preventive doses include drowsiness or daytime sleepiness, dry mouth, constipation, epigastric discomfort, dizziness or blurred vision, and weight gain of about 1 kg over 3 months at 25 mg, with orthostatic hypotension a notable risk that merits counseling, while rare but serious events include cardiac arrhythmias or conduction block, hepatic dysfunction, and blood dyscrasias that warrant prompt evaluation if suspected [^1178b2Ap] [^113HvkKM] [^114bjYhF] [^112KqeDe]. If any of these emerge in a way that impairs safety or function, I should confirm dose timing, consider dose reduction or slower titration, and reassess the choice of preventive with the patient, given alternative first-line options are available if tolerability is limiting [^114wvNRq] [^111vLknW].

---

Amitriptyline is effective for migraine prevention [^111ZpTG6], but **side effects are common** and often emerge within days to weeks of initiation [^1178b2Ap] [^112KqeDe]. The most frequent early adverse effects are **sedation and dry mouth** [^1178b2Ap] [^112KqeDe]; other anticholinergic and cardiovascular effects are also reported [^114bjYhF].

---

## Common early side effects

The **most frequently reported early side effects** of amitriptyline for migraine prophylaxis include:

- **Sedation/drowsiness**: Very common [^112KqeDe], often occurring within the first few days of treatment [^1178b2Ap].

- **Dry mouth (xerostomia)**: Very common [^112KqeDe], typically appearing early in treatment [^1178b2Ap].

- **Constipation**: Common [^112KqeDe], usually developing within the first week [^1178b2Ap].

- **Dizziness**: Common [^112KqeDe], often occurring shortly after initiation [^1178b2Ap] [^11659CuF].

- **Weight gain**: Common [^1178b2Ap], with significant weight gain observed within the first few weeks.

- **Blurred vision**: Common [^112KqeDe], typically appearing early due to anticholinergic effects.

- **Orthostatic hypotension**: Very common [^114bjYhF], often occurring within the first few days [^112KqeDe].

---

## Less common but clinically significant early side effects

- **Cardiovascular effects**: Tachycardia, palpitations, and arrhythmias may occur early [^112KqeDe], particularly in patients with pre-existing cardiovascular conditions.

- **Neuropsychiatric symptoms**: Anxiety, agitation, confusion, and vivid dreams may appear early in treatment [^112KqeDe] [^113UzSCy].

- **Gastrointestinal symptoms**: Nausea, epigastric discomfort, and bloating may occur shortly after initiation [^112KqeDe] [^1178b2Ap].

---

## Clinical implications and management strategies

Given the frequency and potential severity of early side effects, **clinicians should**:

- **Start low and go slow**: Initiate at low doses (e.g. 10–25 mg nightly) and titrate gradually to minimize side effects [^1114kAYC] [^116qdqh7].

- **Patient education**: Inform patients about common early side effects and provide strategies to manage them (e.g. hydration, dietary fiber, slow position changes) [^1114kAYC].

- **Monitor closely**: Regularly assess for side effects, especially sedation, orthostatic hypotension, and cardiovascular symptoms [^114bjYhF] [^112KqeDe].

- **Consider alternatives**: If side effects are intolerable, consider alternative migraine prophylactic medications such as beta-blockers [^11363dJ4], anticonvulsants [^116d9yZE], or CGRP inhibitors [^117AURMY] [^111vLknW].

---

## Summary table of early side effects

| **Side effect** | **Frequency** | **Onset** |
|-|-|-|
| Sedation/drowsiness | Very common | Days |
| Dry mouth | Very common | Days |
| Constipation | Common | Days |
| Dizziness | Common | Days |
| Weight gain | Common | Weeks |
| Blurred vision | Common | Days |
| Orthostatic hypotension | Very common | Days |
| Cardiovascular effects | Less common | Days |
| Neuropsychiatric symptoms | Less common | Days |
| Gastrointestinal symptoms | Less common | Days |

---

Amitriptyline is effective for migraine prevention, but **early side effects are common** and can limit adherence [^1142sqRR] [^113UzSCy] [^116Xp3wV]. Sedation, dry mouth, constipation, dizziness, weight gain, and orthostatic hypotension are the most frequent early adverse effects, typically emerging within days to weeks of initiation [^1178b2Ap] [^114bjYhF].

---

## References

### Randomised clinical trial comparing melatonin 3 mg, amitriptyline 25 mg and placebo for migraine prevention [^1178b2Ap]. Journal of Neurology, Neurosurgery, and Psychiatry (2016). High credibility.

- **Tolerability**: Over the 3-month course of treatment, 77 adverse events were reported by 60 participants: 46 reports in the amitriptyline group, 16 in the melatonin group, and 17 in the placebo group. No serious adverse events were observed. The majority of adverse events were either mild or moderate in intensity and occurred more commonly in the amitriptyline group compared with melatonin and placebo (p < 0.03), whereas the melatonin and placebo groups had similar numbers (p value = not significant). The most common adverse events were daytime sleepiness, dry mouth, epigastralgia, weight gain, and constipation. Blood pressure levels did not change among groups. Patients were asked specifically about hypoglycemic symptoms and reported none.

- **Weight variation**: We also evaluated weight variation in all groups. Surprisingly, patients taking melatonin had on average a weight reduction (mean 0.140 ± 0.156 kg), whereas those taking placebo and amitriptyline had a weight gain (mean 0.432 ± 0.247 kg and 0.971 ± 0.359 kg, respectively). Weight differences among groups were significantly different.

---

### SPL drug information for amitriptyline hydrochloride [^114bjYhF]. U.S. Food and Drug Administration. High credibility.

Very common adverse reactions (over 10%) associated with the use of amitriptyline hydrochloride PO (also known as Elavil) include orthostatic hypotension.

---

### Chlordiazepoxide and amitriptyline hydrochloride [^112KqeDe]. U.S. Food and Drug Administration (2025). High credibility.

Adverse reactions: Adverse reactions to chlordiazepoxide and amitriptyline hydrochloride are those associated with the use of either component alone. The most frequently reported symptoms were drowsiness, dry mouth, constipation, blurred vision, dizziness, and bloating. Other side effects occurring less commonly included vivid dreams, impotence, tremor, confusion, and nasal congestion. Many symptoms common to the depressive state, such as anorexia, fatigue, weakness, restlessness, and lethargy, have been reported as side effects of treatment with both chlordiazepoxide and amitriptyline hydrochloride tablets and amitriptyline.

Granulocytopenia, jaundice, and hepatic dysfunction of uncertain etiology have also been observed rarely with chlordiazepoxide and amitriptyline hydrochloride tablets. When treatment with these tablets is prolonged, periodic blood counts and liver function tests are advisable.

- **Note**: Included in the listing which follows are adverse reactions which have not been reported with chlordiazepoxide and amitriptyline hydrochloride. However, they are included because they have been reported during therapy with one or both of the components or closely related drugs.
	- **Cardiovascular**: Hypotension, hypertension, tachycardia, palpitations, myocardial infarction, arrhythmias, heart block, stroke.
	- **Psychiatric**: Euphoria, apprehension, poor concentration, delusions, hallucinations, hypomania, and increased or decreased libido.
	- **Neurologic**: Incoordination, ataxia, numbness, tingling, and paresthesias of the extremities, extrapyramidal symptoms.

---

### Amitriptyline for post-COVID headache: Effectiveness, tolerability, and response predictors [^113YBrdy]. Journal of Neurology (2022). Low credibility.

A complete medical history was obtained from each patient during an in-person clinical interview conducted by a neurologist experienced in headache disorders. The demographic and clinical variables included sex, age, history of migraine and tension-type headache (TTH), history of medication overuse (MOH), anxiety or depression, insomnia, and other concomitant pain. The presence of comorbid psychiatric disorders, including anxiety or depression, was evaluated when amitriptyline was used.

- **Headache-specific variables**: These included prior history of headache, specific headache type, prior number of prophylactics for post-COVID-19 headache if any, and headache phenotype. Intensity was measured by the numerical rating scale (NRS) between 0 (no pain) and 10 (worst possible pain), localization (hemicranial, holocranial), and quality of pain (oppressive, throbbing). Accompanying symptoms included nausea, vomiting, photophobia, phonophobia, osmophobia, allodynia, and worsening with physical activity.

- **Headache variables**: These included the baseline number of headache days per month, baseline number of moderate–severe headache days per month defined as 4–10 on the NRS, baseline urgent care visits per month, and baseline number of acute medication days per month.

- **COVID-19 related variables and AMT use**: These included the time elapsed from COVID-19 to amitriptyline onset, amitriptyline starting dose, maximum amitriptyline dose, time lapsed before doubling the starting dose, amitriptyline duration, amitriptyline dose at adverse effects, and use of NSAIDs and triptans as symptomatic treatment.

All the variables included in the study are available in Supplementary Table 1.

---

### Migraine headache prophylaxis [^116d9yZE]. American Family Physician (2025). High credibility.

The 2025 guidelines from the American Academy of Family Physicians (AAFP) recommend the use of certain anticonvulsants as a first-line option for migraine prophylaxis. Specifically, they advise offering topiramate, divalproex, or valproate for this purpose.

---

### Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition [^116cNEue]. Cephalalgia (2019). High credibility.

- **Headache relief**

- **Recommendations**:
	- Headache relief, defined as the decrease in headache pain from moderate or severe at baseline to mild or none at 2 hours after treatment and before taking any rescue medication (refer to Section 1.2.11), should be used as a secondary efficacy measure. A time point before 2 hours after treatment can be used when testing parenteral treatments.

- **Comments**:
	- Headache relief should be used as an outcome measure, but only as a secondary endpoint and mainly to facilitate comparison of the results of new clinical trials with those of previous programs. Since headache relief is associated with relief of disability, it can be used in clinical trials as a proxy for pain improvement and restoration of function. Headache relief is also useful for comprehensive cost of treatment analyses.

	- In older acute migraine clinical trials, headache relief at 2 hours after treatment was used extensively as a primary efficacy outcome based on the suggestion that patients may consider an acute treatment effective while residual headache pain persists. The validity of this argument has been challenged by evidence showing that patients do not believe a reduction in headache pain from moderate to mild constitutes success and expect acute treatment to provide freedom from pain. In addition, the headache relief endpoint assumes that the magnitude of change from severe pain to no pain is clinically equivalent to the change from moderate pain to mild pain, which is not the case.

---

### Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults [^111L3bEB]. Cephalalgia (2008). Low credibility.

In 1991, the Clinical Trials Subcommittee of the International Headache Society (IHS) developed and published its first edition of the guidelines on controlled trials of drugs in episodic migraine. This was because only quality trials can form the basis for international collaboration on drug therapy, and these guidelines would "improve the quality of controlled clinical trials in migraine". With the trend for large multinational trials, there is a need for increased awareness of methodological issues in clinical trials of drugs and other treatments for chronic migraine. These guidelines are intended to assist in the design of well-controlled clinical trials of chronic migraine in adults and do not apply to studies in children or adolescents.

---

### Topamax [^115m1pMW]. U.S. Food and Drug Administration (2025). High credibility.

The results of two multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trials established the effectiveness of Topamax in the preventive treatment of migraine. The design of both trials — Study 11, conducted in the US, and Study 12, conducted in the U.S. and Canada — was identical. They enrolled patients with a history of migraine, with or without aura, for at least six months, according to the International Headache Society (IHS) diagnostic criteria. Patients with a history of cluster headaches or basilar, ophthalmoplegic, hemiplegic, or transformed migraine headaches were excluded from the trials. Additionally, patients were required to complete up to a two-week washout of any prior migraine preventive medications before starting the baseline phase.

Patients who experienced 3 to 12 migraine headaches over the four weeks in the baseline phase were randomized to receive either Topamax 50 mg/day, 100 mg/day, 200 mg/day, or placebo. They were treated for a total of 26 weeks, which included an 8-week titration period and an 18-week maintenance period. Treatment was initiated at 25 mg/day for one week, with the daily dosage increased by 25 mg increments each week until reaching the assigned target dose or the maximum tolerated dose, administered twice daily.

---

### Chronic daily headache: Diagnosis and management [^1147PJoe]. American Family Physician (2014). High credibility.

Regarding medical management for tension-type headache, particularly in terms of prophylactic therapy, the AAFP 2014 guidelines recommend considering amitriptyline to reduce the duration and severity of headaches in patients with chronic tension-type headache.

---

### Prevention of episodic migraine headache using pharmacologic treatments in outpatient settings: A clinical guideline from the American College of Physicians [^116Chkj6]. Annals of Internal Medicine (2025). High credibility.

The American College of Physicians (ACP) developed this clinical guideline for clinicians caring for adults with episodic migraine headache (defined as 1 to 14 headache days per month) in outpatient settings.

- **Methods**: ACP based these recommendations on systematic reviews of the comparative benefits and harms of pharmacologic treatments to prevent episodic migraine, patients' values and preferences, and economic evidence. ACP evaluated the comparative effectiveness of the following interventions: angiotensin-converting enzyme inhibitors (lisinopril), angiotensin II-receptor blockers (candesartan and telmisartan), antiseizure medications (valproate and topiramate), β-blockers (metoprolol and propranolol), calcitonin gene-related peptide (CGRP) antagonist-gepants (atogepant or rimegepant), CGRP monoclonal antibodies (eptinezumab, erenumab, fremanezumab, or galcanezumab), selective serotonin reuptake inhibitors and serotonin and norepinephrine reuptake inhibitors (fluoxetine and venlafaxine), and a tricyclic antidepressant (amitriptyline).

ACP used the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach to analyze the effects of pharmacologic treatment on the following outcomes: migraine frequency and duration, number of days medication was taken for acute treatment of migraine, frequency of migraine-related emergency department visits, migraine-related disability, quality of life and physical functioning, and discontinuations due to adverse events. In addition, adverse events were captured through U.S. Food and Drug Administration monitoring.

---

### Nonpharmacologic treatment of migraine with low-dose propranolol or amitriptyline [^1149Xjrd]. Pediatric Neurology (2012). Low credibility.

This study evaluated the effectiveness of nonpharmacologic measures combined with low-dose propranolol or amitriptyline for treating severe pediatric migraine. Data were collected from the medical files of 118 patients (mean age, 12.54 ± 3.14 years S.D.). All patients were treated with nonpharmacologic measures. Additionally, 93 children received propranolol (mean initial dose, 0.4 ± 0.17 mg/kg/day S.D.), and 25 received amitriptyline (mean initial dose, 0.26 ± 0.1 mg/kg/day S.D.). Twenty patients were switched from propranolol to amitriptyline during treatment.

In both groups, headache frequency was reduced by more than 50% per month in approximately 80% of patients. Patients without aura responded significantly better to propranolol than patients with aura (P = 0.02). No significant difference was evident in response to pharmacologic treatment by migraine frequency or type (episodic or chronic). No significant difference was evident in response to amitriptyline between patients with or without aura. The response rate was higher than previously reported for placebo. Low-dose propranolol and low-dose amitriptyline, when combined with nonpharmacologic measures, are equally effective in reducing the frequency of migraine in children. Propranolol is preferred because of its lower risk of side effects. An additive effect of nonpharmacologic measures may allow for a reduction in drug dose.

---

### Pilot study of amitriptyline in the prophylactic treatment of medication-overuse headache: a 1-year follow-up [^1177bdfX]. Pain Medicine (2014). Low credibility.

This study aims to evaluate the long-term efficacy of low-dose amitriptyline combined with abrupt withdrawal in outpatients with medication-overuse headache (MOH) using an open-label design.

- **Methods**: We evaluated the effectiveness of early introduction of low-dose amitriptyline combined with abrupt withdrawal in outpatients with MOH over a 1-year observational period. The primary outcome measures were the reduction in the number of headache days and days with use of acute headache medication after 3 months and after 12 months. A number of secondary outcome measures, as well as safety and tolerability, were assessed. Responders were defined as patients with a ≥ 50% reduction in headache frequency from baseline and being without medication overuse.

- **Results**: Thirty-three patients completed the study. Significant reductions in headache frequency and medication consumption were observed at both months 3 and 12, compared to baseline (P < 0.05 for all). Neither the primary nor the secondary endpoints differed significantly between months 3 and 12. At the 12-month follow-up, 58% of the patients were considered responders (N = 19); 73% remained cured of MOH (N = 24); 64% had reverted to episodic headaches (N = 21); 27% had relapsed into MOH (N = 9).

- **Conclusion**: Given these results, early introduction of low-dose amitriptyline combined with abrupt withdrawal could be considered a choice for patients with MOH.

---

### An open pilot study assessing the benefits of quetiapine for the prevention of migraine refractory to the combination of atenolol, nortriptyline, and flunarizine [^117R4xoY]. Pain Medicine (2010). Low credibility.

Migraine is a prevalent neurological disorder. Although prevention is the core of treatment for most, some patients are refractory to standard therapies. Accordingly, the aim of this study was to evaluate the use of quetiapine (QTP) in the preventive treatment of refractory migraine, defined as previous unresponsiveness to the combination of atenolol, nortriptyline, and flunarizine.

- **Methods**: Thirty-four consecutive patients (30 women and 4 men) with migraine (ICHD-II), fewer than 15 days of headache per month, and not overusing symptomatic medications were studied. All participants had failed to achieve a < 50% reduction in attack frequency after 10 weeks of treatment with atenolol (60 mg/day), nortriptyline (25 mg/day), and flunarizine (3 mg/day). After other medications were discontinued, QTP was initiated at a single daily dose of 25 mg, and then titrated to 75 mg. After 10 weeks, headache frequency, consumption of rescue medications, and adverse events were analyzed.

- **Results**: Twenty-nine patients completed the study; three withdrew and two were lost to follow-up. Among those who completed, 22 (75.9%; 64.7% of the intention-to-treat population) experienced greater than 50% headache reduction. The mean frequency of migraine days decreased from 10.2 to 6.2 per month, and the use of rescue medications decreased from 2.3 to 1.2 days/week. Adverse events were reported by nine (31%) patients.

- **Conclusions**: Although limited by the open design, this study provides pilot data to support the use of QTP in the preventive treatment of refractory migraine.

---

### Amitriptyline for post-COVID headache: effectiveness, tolerability, and response predictors [^111YjNiD]. Journal of Neurology (2022). Low credibility.

During the study period, 48 patients fulfilled eligibility criteria. Of these, 40 out of 48 (83.3%) were female. Among the patients with a prior history of migraine or tension-type headache (TTH), 12 out of 20 (60%) had received prophylactic treatment, with a median number of prophylactic treatments being 1 (IQR: 0–1). Regarding amitriptyline (AMT), 6 out of 20 (30%) had previously received it as a prophylactic treatment for their primary headache, and thus, 6 out of 48 (12.5%) had been exposed to AMT before their COVID-19 headache. At the time of AMT initiation, the mean age of patients was 46.8 years (SD: 13.6). A history of migraine was present in 15 out of 48 (31.3%), a history of TTH in 5 out of 48 (10.4%), and a prior history of medication-overuse headache (MOH) in 1 out of 48 (2.1%).

Among other comorbidities, anxiety or depression were present in 11 out of 48 (22.9%) of cases, a prior history of insomnia in 11 out of 48 (22.9%), and other concomitant pain syndromes in 7 out of 48 (14.6%) patients. The median number of prior prophylactic treatments for post-COVID-19 headache was 0 (0–1).

- **Post-COVID-19 headache characteristics**: Post-COVID-19 headache presented a median pain intensity of 7 [IQR: 5.2–9] on a numerical rating scale (NRS). It had a holocranial location in 38 out of 48 (79%), an oppressive quality in 44 out of 48 (91%), and a throbbing quality in 12 out of 48 (25%) of cases. Accompanying symptoms included nausea in 16 out of 48 (33.3%).

---

### Tricyclic antidepressants and headaches: Systematic review and meta-analysis [^112p1JGY]. BMJ (2010). Low credibility.

Study quality was generally low. Few studies performed an intention-to-treat analysis, which is particularly concerning as some trials experienced up to 50% losses to follow-up. Patients who experienced significant adverse effects or showed a lack of improvement were likely to drop out. Although we found no difference in effect estimates between trials that did and did not conduct an intention-to-treat analysis, our sample size was relatively small.

The heterogeneity of our results was considerable, especially among individuals with tension-type headaches. Study duration explained some, but not all, of the variance. Additionally, there was evidence of small study effects, commonly known as publication bias. Tests designed to estimate the number of unpublished trials necessary to nullify results, and tests to "fill in" missing studies, have been criticized for lacking theoretical foundation, poor simulation performance, and a tendency to overestimate effects, particularly in the presence of heterogeneity. Small, negative trials are less likely to be published, and missing trials generally decrease the efficacy estimate.

It is important to consider two potential sources of confounding. Firstly, the treatment effect might be real; effective treatments may also show evidence of publication bias. Secondly, tests for publication bias tend to overestimate the risk of bias in the face of heterogeneity. It is possible, and indeed probable, that unpublished trials exist.

---

### Amitriptyline in the prophylaxis of central poststroke pain. Preliminary results of 39 patients in a placebo-controlled, long-term study [^111qh6R9]. Stroke (2002). Low credibility.

We performed a double-blind, placebo-controlled study to investigate the effectiveness of amitriptyline for the prophylactic treatment of patients with acute thalamic stroke in preventing central poststroke pain. Subjects received, in a randomized sequence, either amitriptyline titrated from 10 to 75 mg in extended-release form or placebo over a therapy period of 365 days. We documented the time when pain developed; the intensity, type, site, and distribution of pain; and the presence or absence and type of allodynia.

Thirty-nine patients (23 women and 16 men; age range, 36 to 68 years) with central poststroke pain participated. The placebo group showed a pain rate of 21% within 1 year after the diagnosis of thalamic stroke compared with 17% in the group under prophylactic treatment with amitriptyline. The average (SE) time to pain was 318 (23) days for patients in the placebo group and 324 (24) days for patients in the amitriptyline group.

With the achieved sample sizes of this study and a pain rate of approximately 21% in the placebo group, any near-perfect pain protection would have been detected. Near-perfect pain protection, in this context, refers to pain in less than 2.4% of the recruited patients treated with amitriptyline or in approximately 89% of placebo-treated patients. Larger studies are recommended to test the hypothesis that prophylactic amitriptyline reduces but does not completely prevent central poststroke pain.

---

### Medications for migraine prophylaxis [^1128uVZ9]. American Family Physician (2006). Low credibility.

Sufficient evidence and consensus exist to recommend propranolol, timolol, amitriptyline, divalproex, sodium valproate, and topiramate as first-line agents for migraine prevention. There is fair evidence of effectiveness with gabapentin and naproxen sodium. Botulinum toxin has also demonstrated fair effectiveness, but further studies are needed to define its role in migraine prevention. Limited evidence supports the use of candesartan, lisinopril, atenolol, metoprolol, nadolol, fluoxetine, magnesium, vitamin B2 (riboflavin), coenzyme Q10, and hormone therapy in migraine prevention. Data and expert opinion are mixed regarding agents such as verapamil and feverfew; these can be considered in migraine prevention when other medications cannot be used. Evidence supports the use of timed-release dihydroergotamine mesylate, but patients should be monitored closely for adverse effects.

---

### Diagnosis and management of migraine in ten steps [^1147fHrh]. Nature Reviews Neurology (2021). Low credibility.

In patients with apparent late-onset migraine, suspect an underlying cause. In older people, consider the higher risks of secondary headache, comorbidities, and adverse events with older age. In children and adolescents with migraine, bed rest alone might suffice. If not effective, use ibuprofen for acute treatment and propranolol, amitriptyline, or topiramate for prevention. In pregnant or breastfeeding women, use paracetamol for acute treatment and avoid preventive medication whenever possible. In women with menstrual migraine, consider perimenstrual preventive therapy with a long-acting NSAID or triptan.

---

### Amitriptyline for fibromyalgia in adults [^112BqytG]. The Cochrane Database of Systematic Reviews (2019). Low credibility.

This updated version of the original Cochrane review, published in Issue 12, 2012, originally considered both fibromyalgia and neuropathic pain. However, the efficacy of amitriptyline for neuropathic pain is now addressed in a separate review. Amitriptyline, a tricyclic antidepressant, is widely used to treat fibromyalgia and is recommended in many guidelines. It is typically used at doses lower than those required for antidepressant effects.

- **Objectives**: To assess the analgesic efficacy of amitriptyline for relief of fibromyalgia and the adverse events associated with its use in clinical trials.

- **Search methods**: We searched CENTRAL, MEDLINE, and EMBASE up to March 2015, considering reference lists of retrieved papers, previous systematic reviews, other reviews, and two clinical trial registries. We also used our own hand-searched database for older studies.

- **Selection criteria**: We included randomized, double-blind studies lasting at least four weeks, comparing amitriptyline with a placebo or another active treatment in fibromyalgia.

- **Data collection and analysis**: We extracted efficacy and adverse event data, and two study authors independently assessed study quality. We performed analyses using three tiers of evidence. First-tier evidence was derived from data meeting high standards and showing minimal risk of bias, including substantial pain intensity reduction, intention-to-treat analysis without imputation for dropouts; involving at least 200 participants, with an 8 to 12-week duration, and parallel design.

---

### Randomised clinical trial comparing melatonin 3 mg, amitriptyline 25 mg and placebo for migraine prevention [^112fW4YV]. Journal of Neurology, Neurosurgery, and Psychiatry (2016). Low credibility.

- **Outcome measures**: The primary efficacy outcome measure was the frequency in the number of migraine headache days per month, comparing baseline with the past 4 weeks of treatment. Secondary endpoints included reduction in migraine intensity, attack duration, the number of analgesics used, and percentages of patients with greater than 50% reductions in migraine headache days.

- **Tolerability and safety**: Patients were monitored by adverse events and vital signs to determine tolerability and safety. An adverse event was defined as any medical occurrence reported by a patient or noted by a clinician during the study, regardless of its suspected cause. It was recorded if it was considered to be related to study medication. Tolerability measures included the incidences of adverse events, including those that led to the premature withdrawal of the study and serious adverse events (defined as death, disability or incapacity; were life-threatening; or required hospitalisation). Adverse events data were summarised for the safety population, defined as randomised patients who were administered at least one dose of the study medication.

---

### Rizatriptan for acute migraine headaches in adults [^113fF5vf]. The Cochrane Database of Systematic Reviews (2010). Low credibility.

The protocol for this review does not include an abstract. The objective of the review is to determine the efficacy and tolerability of rizatriptan compared to placebo and other active interventions in the treatment of acute migraine headaches in adults.

---

### Randomised clinical trial comparing melatonin 3 mg, amitriptyline 25 mg and placebo for migraine prevention [^116dR2Wc]. Journal of Neurology, Neurosurgery, and Psychiatry (2016). Low credibility.

- **Results**

- **Patients**: The number of patients randomised to treatment was 196 after 438 were recruited and assessed for eligibility. Eighteen randomised patients were excluded from the study; the analysis was performed in the remaining completed cases, 178 patients (59 placebo, 60 melatonin, and 59 amitriptyline). Between 69% and 75% of patients completed the study in the treatment groups. Adverse event occurrence was the most common reason for premature withdrawal for all randomised patients.

- **Study enrolment and randomisation**: Treatment groups presented with similar demographics and baseline clinical characteristics. There were no significant differences in all variables.

- **The primary efficacy end point** was frequency in the number of migraine headache days per month. Melatonin 3 mg and amitriptyline 25 mg efficiencies were superior to placebo (p < 0.05) when comparing baseline with the last month of observation.

- **For the secondary end points**, melatonin and amitriptyline were more effective than placebo, reducing the number of analgesics taken, migraine headache attacks duration, and intensity. Melatonin and amitriptyline were equally effective for the primary endpoint, but for the secondary outcomes, additional differences were observed.

---

### Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition [^114T6LJc]. Cephalalgia (2019). High credibility.

- **Design types**: Although both parallel-group and crossover designs may be used, parallel-group designs are preferred. Limited to phase II trials, group-sequential, adaptive treatment, and dose-defining designs may be appropriate.

The parallel-group design has the advantage of simplicity. Parallel-group trials have successfully demonstrated both superiority and similarity among treatments. Multiple-attack, parallel-group designs can be used to assess intra-individual consistency of response, although carry-over effects and intra-individual correlation must be taken into account (refer to Section 1.2.12 for information about consistency of response).

With crossover trial designs, period and carry-over effects may occur, and complexities may be introduced if the tested treatment has notable side effects. Crossover designs can also be used in multiple-attack trials to estimate intra-individual consistency of response with placebo-control groups. In addition, crossover designs allow for the assessment of acute treatment preferences. Subjects who have taken more than one treatment can be asked which treatment they would prefer to take again. Responses to this question reflect subjects' net assessment of benefits and tolerability. Given the popularity of social media, participants in crossover trials should be instructed to refrain from posting about the trial.

Non-traditional clinical trial designs include step-wise, adaptive, enriched designs and futility trials. Adaptive designs allow for the modification of aspects of a trial.

---

### Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention: Report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology and the American Headache Society [^112JVz1n]. Neurology (2019). High credibility.

Regarding specific circumstances for migraine, particularly in pediatric and adolescent patients requiring pharmacologic prophylaxis, the AAN/AHS 2019 guidelines recommend considering the teratogenic effects of topiramate and valproate when prescribing migraine prevention therapy to patients of childbearing potential. It is advised to counsel these patients about the potential effects on fetal and childhood development when offering topiramate or valproate for migraine prevention.

---

### Calcitonin gene-related peptide (CGRP) is a key molecule released in acute migraine attacks-successful translation of basic science to clinical practice [^111arzzN]. Journal of Internal Medicine (2022). Low credibility.

Because CGRP is widely expressed in the body, there is ongoing discussion regarding possible cardiovascular or intestinal side effects. A common question is, why are there so few peripheral effects, and would there not be interactions with pain systems generally? The monoclonal antibodies (mAbs) have now been approved by regulatory authorities, including the FDA and EMA, with more than 500,000 patients on these treatments. Numerous patients have reported that the "CGRP-directed medications have transformed their lives". Interestingly, the mAbs have effects both in episodic migraine (EM) and chronic migraine (CM) patients who have not responded well to other available preventive treatments. The American Headache Society has provided a statement paper indicating which patients should receive mAbs for migraine prophylaxis.

---

### Spreading depression: From serendipity to targeted therapy in migraine prophylaxis [^111gLDdY]. Cephalalgia (2009). Low credibility.

Despite the relatively well-characterized headache mechanisms in migraine, upstream events triggering individual attacks are poorly understood. This lack of mechanistic insight has hampered a rational approach to prophylactic drug discovery. Unlike targeted abortive and analgesic interventions, mainstream migraine prophylaxis has been largely based on serendipitous observations (e.g. propranolol) and presumed class effects (e.g. anticonvulsants). Recent studies suggest that spreading depression is the final common pathophysiological target for several established or investigational migraine prophylactic drugs. Building on these observations, spreading depression can now be explored for its predictive utility as a preclinical drug screening paradigm in migraine prophylaxis.

---

### Prevention of episodic migraine headache using pharmacologic treatments in outpatient settings: A clinical guideline from the American College of Physicians [^111vLknW]. Annals of Internal Medicine (2025). High credibility.

Regarding preventative measures for migraine, particularly in terms of migraine prophylaxis, the CGRP inhibitors outlined in the ACP 2025 guidelines recommend considering monotherapy with a CGRP antagonist (atogepant or rimegepant) or a CGRP antibody (eptinezumab, erenumab, fremanezumab, or galcanezumab). This is specifically for the prevention of episodic migraine in nonpregnant adults in outpatient settings who do not tolerate or inadequately respond to a trial or trials of a β-blocker (metoprolol or propranolol), valproate, venlafaxine, or amitriptyline.

---

### Tricyclic antidepressants and headaches: Systematic review and meta-analysis [^1142Jf4N]. BMJ (2010). Low credibility.

Few studies have compared tricyclic antidepressants with other modalities for headache treatment. Notably, no studies have compared β-blockers and tricyclics for tension-type headaches. Among three studies examining migraine headaches, no significant difference was found between tricyclics and β-blockers in reducing the number of headaches or attacks, with an average standardized mean difference of 0.90 (95% confidence interval: -0.38 to 2.18, I² = 93.8%). Additionally, in two studies, the likelihood of experiencing at least a 50% reduction in the number of headaches was similar for both treatments (relative risk 0.78, 95% confidence interval: 0.42 to 1.44, I² = 0.0%). The studies primarily utilized amitriptyline and clomipramine, both at an average dose of 100 mg.

Two studies on tension-type headaches compared tricyclics with buspirone (amitriptyline 50 mg) and found no differences, with buspirone showing an average standardized mean difference of -1.01 (95% confidence interval: -1.83 to -0.18, I² = 0.00%). Another two studies compared tricyclics (amitriptyline 25 mg, clomipramine 150 mg) with tetracyclics, resulting in no significant difference (average standardized mean difference -0.21, 95% confidence interval: -0.65 to 0.22, I² = 32.8%). A single study on tension-type headaches found no difference between low-dose amitriptyline (25 mg) and the serotonin antagonist ritanserin, with a standardized mean difference of -0.49 (95% confidence interval: -1.70 to 0.71).

Conversely, one study found that amitriptyline (75 mg) was more effective than timed-release dihydroergotamine for migraines, with a significant difference of -6.57 (95% confidence interval: -8.44 to -4.71). Additionally, two trials compared amitriptyline (maximum doses 100 mg and 150 mg) with the anticonvulsant topiramate, and found no notable difference (standardized mean difference 0.05, 95% confidence interval: -0.32 to 0.33, I² = 29.2%).

---

### Comparison of the effects of amitriptyline and flunarizine on weight gain and serum leptin, C peptide and insulin levels when used as migraine preventive treatment [^1156ZAwU]. Cephalalgia (2005). Low credibility.

The tricyclic antidepressant amitriptyline (AMT) and the calcium channel blocker flunarizine are frequently used in the preventive treatment of migraine. However, the side effect of prominent weight gain that often emerges during the preventive treatment of migraine with these agents frequently leads to the discontinuation of therapy. In this study, we aimed to investigate the possible relationship between the weight gain associated with the use of these agents and serum levels of leptin, C-peptide, and insulin in patients with migraine. Forty-nine migraine patients with a body mass index (BMI) < 25, without any endocrinological, immunological, or chronic diseases, were randomly divided into two groups, receiving AMT or flunarizine. There was a statistically significant increase in serum levels of leptin, C-peptide, insulin, and measures of BMI in both groups when measured at the 12th week of therapy compared to their respective basal levels. To our knowledge, this is the first study investigating the effects of AMT and flunarizine on serum leptin levels in the preventive use of migraine treatment. A result from this study indicates that AMT and flunarizine may cause leptin resistance possibly by different mechanisms, thereby resulting in an increase in serum leptin levels and BMI.

---

### Randomised clinical trial comparing melatonin 3 mg, amitriptyline 25 mg and placebo for migraine prevention [^11659CuF]. Journal of Neurology, Neurosurgery, and Psychiatry (2016). Low credibility.

The study was designed according to the International Headache Society guidelines for clinical trials, including an active comparator to improve blinding of treatment groups. Patients in the placebo group who do not experience sleepiness might guess their treatment assignment. Amitriptyline 25 mg was chosen as it is lower than the usual dose prescribed in the United States but common in other countries, such as Brazil.

One study showed that topiramate and amitriptyline were equally effective, with mean daily doses of 74.8 mg and 76.5 mg, respectively. However, the amitriptyline group reported side effects deemed unacceptable within our patient population, including dry mouth (35.5%), fatigue (24.3%), somnolence (17.8%), weight increase (13.6%), and dizziness (10.7%). While higher doses of amitriptyline might yield better results, they would likely lead to increased dropout rates in our population.

Although our primary focus was on studying melatonin efficacy, and the trial was not designed for non-inferiority, the results also support the use of amitriptyline in lower doses for migraine prophylaxis.

---

### Randomised clinical trial comparing melatonin 3 mg, amitriptyline 25 mg and placebo for migraine prevention [^113HvkKM]. Journal of Neurology, Neurosurgery, and Psychiatry (2016). High credibility.

Melatonin was more tolerable than amitriptyline and as tolerable as placebo. Weight loss was found in the melatonin group as opposed to a slight weight gain in the placebo and a significant one in the amitriptyline group. This is a very important and original finding that deserves special discussion. There is substantial experimental evidence in the literature indicating the role of melatonin in the control of food intake, energy balance, and body weight. An inhibitory action of melatonin in preadipocytes' differentiation into adipocytes, reducing the number of cells in the visceral adipose tissue, has been demonstrated. Melatonin treatment reduced body weight gain, visceral adiposity, blood triglycerides, and insulin resistance in a model of high-calorie diet-induced metabolic syndrome. Likewise, a single daily administration of melatonin decreased visceral fat in middle-aged mice, and after melatonin treatment, aged rats showed weight reduction, preceded by an increase in insulin signaling in the central nervous system (CNS) and peripheral tissues. In addition, melatonin might have a direct anorexigenic action regulating hypothalamic pro-opiomelanocortin (POMC) gene expression. In aging animals, melatonin and moderate exercise training induced a reduction in food intake associated with a reduction in body weight and amount of visceral adipose tissue depot. Melatonin should be considered as regulating the other side of energy balance by increasing energy expenditure through its ability to convert white adipose tissue into brown adipose tissue, increasing its metabolic rate.

---

### SPL drug information for nortriptyline hydrochloride [^112igE2F]. U.S. Food and Drug Administration. High credibility.

The dosage of nortriptyline hydrochloride PO for the prevention of migraine attacks in adults is as follows: Start at 10–25 mg PO qHS. Maintenance dosage is 10–50 mg PO qHS.

---

### Prevention of episodic migraine headache using pharmacologic treatments in outpatient settings: A clinical guideline from the American College of Physicians [^114wvNRq]. Annals of Internal Medicine (2025). High credibility.

Regarding preventative measures for migraine, specifically in relation to migraine prophylaxis, the ACP 2025 guidelines recommend considering the initiation of monotherapy with a β-blocker (metoprolol or propranolol), valproate, venlafaxine, or amitriptyline for the prevention of episodic migraine in nonpregnant adults in outpatient settings.

---

### Propranolol for migraine prophylaxis [^113yy3dN]. The Cochrane Database of Systematic Reviews (2004). Low credibility.

Propranolol is one of the most commonly prescribed drugs for migraine prophylaxis.

- **Objectives**: We aimed to determine whether there is evidence that propranolol is more effective than placebo and as effective as other drugs for the interval (prophylactic) treatment of patients with migraine.

- **Search strategy**: Potentially eligible studies were identified by searching MEDLINE/PubMed (1966 to May 2003) and the Cochrane Central Register of Controlled Trials (Issue 2, 2003), and by screening bibliographies of reviews and identified articles.

- **Selection criteria**: We included randomized and quasi-randomized clinical trials of at least 4 weeks duration comparing clinical effects of propranolol with placebo or another drug in adult migraine sufferers.

- **Data collection and analysis**: Two reviewers extracted information on patients, methods, interventions, outcomes measured, and results using a pre-tested form. Study quality was assessed using two checklists (Jadad scale and Delphi list). Due to the heterogeneity of outcome measures and insufficient reporting of the data, only selective quantitative meta-analyses were performed. As far as possible, effect size estimates were calculated for single trials. In addition, results were summarised descriptively and by a vote count among the reviewers.

- **Main results**: A total of 58 trials with 5072 participants met the inclusion criteria. The 58 selected trials included 26 comparisons with placebo and 47 comparisons with other drugs. The methodological quality of the majority of trials was unsatisfactory. The principal shortcomings…

---

### What efficacy measures are clinically relevant and should be used in Cochrane reviews of acute migraine trials? An alternative viewpoint [^113y9WQS]. Cephalalgia (2015). Low credibility.

I briefly review the purposes of efficacy measures, which go far beyond supporting new drug development. I use vignettes to illustrate the importance of functional recovery during the migraine attack and argue that headache relief provides this. Sustained headache relief (SHR) is therefore a very worthwhile outcome when the alternative is a day of debilitating pain. As a measure, SHR may not be ideal for new drug development, but it is informative to individuals, health care providers, and politicians, and serves cost-effectiveness analysis better than any other. Cochrane are absolutely right to use it in systematic reviews along with the IHS-recommended measures.

---

### Tricyclic antidepressants and headaches: Systematic review and meta-analysis [^113UzSCy]. BMJ (2010). Low credibility.

The effects of tricyclic antidepressants (TCAs) on the burden of headaches for tension-type and migraine headaches were analyzed and compared with placebo. Trials involving mixed and migraine headaches were combined.

The number of headaches per month was reduced on average by 6.9 for tension-type headaches (95% confidence interval: −21.6 to 7.7, three studies) and by 1.4 for migraine headaches (−3.3 to 0.5, four studies). For both headache types, the beneficial effect increased over time. For tension-type headaches: β = −0.16 (95% confidence interval: −0.23 to −0.10, P < 0.0005), and for migraine headaches: β = −0.09 (−0.14 to −0.04, P = 0.001). Therefore, for every additional week of treatment with a tricyclic, the number of headaches was reduced by 0.16 standard deviations.

A range of tricyclic doses was used in these trials, with an average dose that was 50% of the maximum for the particular tricyclic studied. The effect of doses less than 50% of the maximum was lower than those with higher doses (average standardized mean difference: −0.73, 95% confidence interval: −1.14 to −0.32 vs. −0.92, −1.50 to −0.34), although the difference was not significant (P = 0.34).

Patients taking tricyclics were more likely to experience at least a 50% improvement in their headaches compared to those taking placebo for both tension-type headaches (relative risk: 1.41, 95% confidence interval: 1.02 to 1.89, four studies, I² = 48.8%) and migraine headaches (1.80, 1.24 to 2.62, four studies, I² = 0.0%).

---

### Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition [^116XHMJM]. Cephalalgia (2019). Low credibility.

- **Stratification**: Recommendations for stratification in acute treatment trials are as follows. There is usually no need for stratification. However, it may be considered when there is an imbalance between the treatment groups or when an important factor might influence the results.

	- Randomization alone may not ensure full comparability between subjects in different treatment groups, especially in smaller trials, and stratified randomization is sometimes used to circumvent potential imbalances. The European Medicines Agency (EMA) recommends that stratification variables usually be included as covariates in primary analyses, regardless of their prognostic value. In controlled trials for migraine, the use of stratification by prognostic factors should be limited to a few variables, specifically those that have historically demonstrated effects on primary efficacy endpoints. Stratification variables used in acute treatment trials include age, body weight, headache intensity at baseline, migraine type (i.e. with or without aura), menstrual versus non-menstrual attacks, and concomitant preventive treatment. Given the preponderance of females with migraine, sex may also be used as a stratification factor to control for imbalances in treatment groups.

- **Intention to treat**: Recommendations for randomized controlled trials of acute treatments for migraine include following the principle of intention to treat (ITT). This implies that analyses should include all randomized subjects in the groups to which they were randomly assigned, regardless of the treatment received.

---

### Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society [^116wsq5D]. Neurology (2019). High credibility.

Regarding specific circumstances for migraine, particularly in pediatric and adolescent patients, the AAN/AHS 2019 guidelines recommend discussing the evidence for amitriptyline combined with CBT for migraine prevention. It is important to inform patients of the potential side effects of amitriptyline, including the risk of suicide, and collaborate with families to identify providers offering this type of treatment.

---

### Efficacy and feasibility of antidepressants for the prevention of migraine in adults: A meta-analysis [^111KPc3f]. European Journal of Neurology (2017). Low credibility.

Migraine has greatly impacted the quality of life for migraineurs and was ranked as the seventh highest specific cause of disability worldwide in 2012. Because of the role of serotonin in migraine mechanisms, antidepressants have been used in the prevention of migraine. However, the role of antidepressants for migraine prophylaxis in adults has not been completely established. Our aim was to systematically assess the efficacy and feasibility of antidepressants for the prevention of migraine in adults based on currently available literature.

- **Methods**: A comprehensive search of databases was conducted, including the Cochrane, PubMed, Web of Science, and Embase databases, from inception to July 2016. Randomized controlled trials that assigned adults with a clinical diagnosis of migraine to antidepressant or placebo treatment were included. The primary outcome was the reduction of migraine frequency or index.

- **Results**: Overall, 16 randomized controlled trials including 1,082 participants were identified. Antidepressants had a significant advantage over placebo in reducing the migraine frequency or index of adults, with a standardized mean difference of -0.79 [95% confidence interval (CI) -1.13 to -0.45, P < 0.00001]. Patients receiving antidepressant therapy were more likely to experience at least a 50% reduction of headache burden than those receiving placebo (28.9% vs. 20.2%; risk ratio 1.40; 95% CI 0.97–2.02; P = 0.07). However, antidepressants were less well tolerated than placebo due to some adverse events (risk ratio 1.74, 95% CI 1.05–2.89, P = 0.0).

---

### Tricyclic antidepressants and headaches: Systematic review and meta-analysis [^114tUFfD]. BMJ (2010). Low credibility.

Overall, 1471 potential articles were identified. On the initial screen, 443 full-text articles were retrieved and assessed for eligibility (see fig 1). Thirty-seven studies met the inclusion criteria: 13 focused on migraine headaches, 17 on tension-type headaches, six on chronic mixed headaches (components of migraine and tension-type headaches), and one on psychogenic headaches. Six studies used the 1988 criteria of the International Headache Society, 11 used the 1962 ad hoc committee criteria, and the remainder used the most recent criteria. All trials of migraine headaches would meet the most recent criteria. Among trials of tension-type headache, one met the criteria for infrequent episodic headaches, six for frequent episodic headaches, and 15 for chronic headaches according to the most recent criteria. The six trials with mixed headaches were analyzed as migraine headaches as they better met the criteria for migraine headaches than for tension-type headaches.

Twenty-nine of the 37 studies used parallel group designs, and eight used crossover designs. None of the crossover studies provided sufficient data from which to calculate paired within-patient results. All eight were, however, included as one trial, reported no carry-over effect, and the remainder had either more than four weeks of washout or sufficiently long treatment durations to minimize carry-over effects.

A total of 3176 participants were enrolled across the 37 studies. Studies lasted an average of 10 weeks, with a range of 4 to 26 weeks. A mean of 70 participants (range 10–554).

---

### Preventive treatment of migraine: effect on weight [^114JrojX]. Cephalalgia (2005). Low credibility.

Weight gain is a side effect commonly associated with drugs used for headache prophylaxis. This weight gain can adversely affect patient health, exacerbate comorbid metabolic disorders, and encourage noncompliance. Few studies have been conducted specifically on the effect of headache medications on weight. It is important for physicians to have accurate information about weight-gain side effects when identifying appropriate pharmacological regimens. This review discusses the potential effects on weight of the more common headache medications.

---

### Acupuncture versus standard medical care in the prophylactic treatment of migraine: A systematic review and meta-analysis [^111etwnR]. European Journal of Neurology (2025). Low credibility.

Although innovative pharmacological therapies for migraine prevention are now available, they may not be suitable or effective for all patients due to concerns about tolerability and the varying complexity of the underlying condition. This study systematically reviewed and meta-analyzed acupuncture's effects on migraine prophylaxis compared to standard medical care, focusing on study heterogeneity and issues related to sham interventions.

Following the PRISMA guidelines and using the PICO model, the study searched PubMed, Scopus, CNKI, and VIP databases from December 1965 to September 2024. Studies evaluating acupuncture's clinical efficacy for migraine prophylaxis, including clinical trials, observational studies, case series, and case reports, were considered. An additional search was conducted on the databases from the beginning of indexing up to September 2024 to include ongoing studies. Quality control and bias assessment were performed. Primary outcomes focused on acupuncture's efficacy and safety versus pharmacological treatments in reducing migraine frequency and intensity. The impact on patients' quality of life was also evaluated.

At the end of the selection process, 15 studies were eligible. Acupuncture showed no statistically significant difference as a prophylactic treatment for migraine in reducing the frequency of migraine days or pain intensity but did reduce the use of analgesics while improving patients' quality of life. Evidence supports acupuncture as an adjunctive therapy in migraine prophylaxis.

---

### Randomised clinical trial comparing melatonin 3 mg, amitriptyline 25 mg and placebo for migraine prevention [^1142sqRR]. Journal of Neurology, Neurosurgery, and Psychiatry (2016). High credibility.

Melatonin has been studied in headache disorders. Amitriptyline is efficacious for migraine prevention; however, its unfavorable side effect profile limits its use.

- **Methods**: A randomized, double-blind, placebo-controlled study was carried out. Men and women, aged 18–65 years, with migraine with or without aura, experiencing 2–8 attacks per month, were enrolled. After a 4-week baseline phase, 196 participants were randomized to placebo, amitriptyline 25 mg, or melatonin 3 mg. A total of 178 participants took a study medication and were followed for 3 months (12 weeks). The primary outcome was the number of migraine headache days per month at baseline versus the last month. Secondary endpoints were responder rate, migraine intensity, duration, and analgesic use. Tolerability was also compared between groups.

- **Results**: Mean headache frequency reduction was 2.7 migraine headache days in the melatonin group, 2.2 for amitriptyline, and 1.1 for placebo. Melatonin significantly reduced headache frequency compared with placebo (p = 0.009), but not compared to amitriptyline (p = 0.19). Melatonin was superior to amitriptyline in the percentage of patients with a greater than 50% reduction in migraine frequency and was better tolerated than amitriptyline. Weight loss was observed in the melatonin group, while slight weight gain occurred in the placebo group, and significant weight gain was noted for amitriptyline users.

- **Conclusions**: Melatonin 3 mg is better than placebo for migraine prevention, more tolerable than amitriptyline, and as effective as amitriptyline 25 mg.

---

### Sumatriptan-naproxen sodium in migraine: A review [^112brBax]. European Journal of Neurology (2024). Low credibility.

Migraine is a highly prevalent, disabling neurological disease marked by attacks of moderate to severe head pain, usually throbbing in quality, that, when left untreated, typically lasts between 4 to 72 hours. It is associated with photophobia, phonophobia, nausea, and/or vomiting. Varied responses to acute medications used for migraine have been observed, with over one-third (34.5%) of patients reporting insufficient headache relief. Migraine has a complex pathophysiology, known only in part, involving multiple components. In this context, multi-mechanistic therapeutic agents have been developed as optimal acute treatment approaches with the physiological rationale of targeting multiple putative mechanisms involved in the pathogenesis of the disorder.

Sumatriptan-naproxen sodium, a single, fixed-dose combination tablet comprising sumatriptan 85 mg and naproxen sodium 500 mg (hereafter denoted sumatriptan-naproxen sodium), was approved by the US Food and Drug Administration in April 2008 and is now approved in several European countries as a prescribed medication. It is formulated as a bilayer tablet that includes RT technology (RT: fast disintegrating/rapid release tablet), enabling rapid disintegration and release of sumatriptan, thereby promoting content dispersal. Triptans and nonsteroidal anti-inflammatory drugs (NSAIDs) may target separate aspects of the potential pathophysiology of migraine. Together, hypothetically, they prevent or reduce both peripheral activation of central pain pathways and central pathway activation during the early stages of a migraine attack.

---

### Migraine headache prophylaxis [^11363dJ4]. American Family Physician (2025). High credibility.

Regarding preventive measures for migraines, particularly migraine prophylaxis, the AAFP 2025 guidelines recommend offering propranolol or metoprolol as first-line options for migraine prophylaxis.

---

### Health technology assessment for the acute and preventive treatment of migraine: A position statement of the International Headache Society [^112qhfNp]. Cephalalgia (2021). Low credibility.

The developers of new health technologies typically conduct randomized trials to demonstrate efficacy using placebo as a control. For health technology assessments (HTAs) in migraine, it is recommended that new technologies be compared with an established treatment in the specific patient population of interest. If head-to-head trials comparing relevant interventions are not available at the time of assessment, HTAs should employ indirect or mixed-treatment comparisons, such as network meta-analyses, to estimate relative effectiveness, provided that the trials being analyzed have comparable treatment periods, endpoints, assessments, and populations. Statistical adjustments for potential confounders of treatment effects should be included whenever required. The HTA process should fully include relevant stakeholders, particularly patients and/or patient groups, including public hearings by the HTA authorities.

- **Acute treatment**: Appropriate comparators for technologies intended for the acute treatment of migraine include the oral tablet formulations of sumatriptan 50 mg, sumatriptan 100 mg, rizatriptan 10 mg, or eletriptan 40 mg and 80 mg. For new technologies intended for patients who do not respond to triptans, do not tolerate them, or have cardiovascular contraindications that preclude their use, appropriate comparators include a different class of medications, such as NSAIDs, usual care, or placebo. With usual care as the comparator, real-world data on headache patterns and treatments are required, and patients who have a history of failure with currently available treatments should be assessed.

---

### SIGN 155 pharmacological management of migraine: A national clinical guideline [^114QFQqB]. SIGN (2023). High credibility.

Regarding preventative measures for migraine, specifically with respect to migraine prophylaxis, the SIGN 2023 guidelines recommend offering propranolol 80–160 mg daily as first-line prophylactic therapy in patients with episodic or chronic migraine.

---

### Randomised clinical trial comparing melatonin 3 mg, amitriptyline 25 mg and placebo for migraine prevention [^116mVt3t]. Journal of Neurology, Neurosurgery, and Psychiatry (2016). Low credibility.

The results from this study support the efficacy and tolerability of melatonin 3 mg as a preventive therapy for migraine. Melatonin was more effective than placebo in the primary endpoint and all other endpoints studied. Although melatonin was as effective as amitriptyline 25 mg in the primary endpoint, in the secondary endpoint, the proportion of patients who improved > 50% in headache frequency, melatonin was superior to both placebo and amitriptyline. The placebo rate in our study was 20.4%, similar to the rates reported in the meta-analysis of pharmacological migraine prevention studies, 22% (0.17% to 0.28%).

A pilot open-label study was published in 2004, showing efficacy and good tolerability of the same melatonin dose as was studied in this trial. A placebo-controlled study comparing a different melatonin compound and dose (extended-release melatonin 2.0 mg, Circadin (Neurim Pharmaceuticals, Tel-Aviv, Israel)) with placebo showed negative results. Several methodological issues, including the short trial length (only 8 weeks), a high placebo response rate, low melatonin dosage, and patient population limits, impact this trial's interpretation. Nevertheless, in this trial, the melatonin response rate was 44%, similar to several other positive migraine prophylaxis trials. The mean decrease in headache frequency was also similar to the most recent and well-designed preventive trials.

---

### Randomised clinical trial comparing melatonin 3 mg, amitriptyline 25 mg and placebo for migraine prevention [^115KUWA3]. Journal of Neurology, Neurosurgery, and Psychiatry (2016). Low credibility.

Statistical analysis was performed with a focus on sample size calculation, which was based on previous trials. A 20% difference between the active drug and placebo response was assumed. The randomisation ratio of 1:1:1 for placebo and the two treatment groups was used. A total of 59 participants per group was determined to provide 80% power to detect a significant difference in the primary endpoint.

This estimate was based on a two-sided analysis of variance (ANOVA), an α level of 0.05, and a standard deviation (SD) of 4.0. Efficacy data were analysed for the intention-to-treat population, defined as randomised patients who received at least one dose of the study medication and provided at least one postbaseline efficacy assessment. No interim analysis was planned.

Missing data were analysed by three methods:

- **Extending the calendar**: The period was extended into the treatment period until 28 days of non-missing data contributed to the count of migraine headache days.
- **Proportional adjustment**: The number of migraine headache days was proportionately adjusted (multiplied by 28 and divided by the number of non-missing days).
- **Treating missing days**: All missing days were treated as non-migraine headache days (used for the primary endpoint).

An analysis of covariance (ANCOVA) model was used to test the null hypothesis of no difference between placebo and the average of the values for the three groups. Results were summarised using the adjusted mean and standard error (SE) for each treatment group, a 95% confidence interval (CI) for the change from baseline for each treatment group, a model estimate of the difference between each active treatment group and placebo, a 95% CI for the difference, and an associated p-value.

---

### Tonabersat for migraine prophylaxis: a systematic review [^114atqHG]. Pain Physician (2014). Low credibility.

Randomized clinical trials assessing the efficacy and tolerability of tonabersat compared with placebo as prophylaxis for migraine were systematically reviewed in this study. By analyzing all available data, we aimed to establish an overall estimate of any association in order to more accurately inform clinicians and caregivers about how to prevent migraines.

- **Objective**: To evaluate the efficacy and tolerability of tonabersat when it is used for migraine prevention.

- **Study design**: Systematic review of tonabersat for migraine prophylaxis.

- **Methods**: A computerized database search of The Cochrane Pain, Palliative & Supportive Care Trials Register, The Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library), PubMed, and EMBASE was conducted for randomized, double-blind, placebo-controlled trials on tonabersat for migraine until January 2013. We also searched ongoing trials. We did not impose any language restrictions. The quality assessment and clinical relevance criteria utilized were the Cochrane Pain, Palliative & Supportive Care review group criteria as utilized for randomized trials.

- **Outcome measures**: The primary outcome measure was the change in mean number of migraine headache days. The secondary outcome measures were change in attacks, responder rates, reduction of the consumption of rescue medication, and adverse events.

- **Results**: For this systematic review, 133 studies were identified. Of these, 131 studies were excluded, and a total of 2 studies (after the removal of duplicate publications) met inclusion criteria for methodological quality.

---

### Tricyclic antidepressants and headaches: Systematic review and meta-analysis [^116cNE7e]. BMJ (2010). Low credibility.

Statistical analysis was conducted by abstracting and pooling data on headache measures according to the following hierarchy: frequency of headache, intensity of headache, and headache index. This approach was based on the recommendations from the reviewers of our Cochrane protocol.

For frequency, we used the number of headache attacks for migraines and the number of days with headaches for tension-type headaches. Intensity data were extracted using the scale employed in each individual study, with some studies utilizing visual analogue scales while others used different continuous measures of intensity. Additionally, many studies employed a "headache index", which typically sums the burden of headache by multiplying frequency with intensity. We also included and pooled data on analgesic use.

Given the variations in measurements of headache burden across studies, standardised differences, also known as effect sizes, were pooled. Conventionally, effect sizes greater than 0.8 are considered large, those between 0.6 and 0.8 are deemed moderate, and those ranging from 0.2 to 0.6 are regarded as small.

---

### A randomized controlled trial of high rate rTMS versus rTMS and amitriptyline in chronic migraine [^112xV2P5]. Pain Physician (2021). High credibility.

Patients with chronic migraine (CM) respond poorly to pharmacological agents, including tricyclic antidepressants, beta-blockers, anticonvulsants, calcium channel blockers, flunarizine, and melatonin. The combination of two or more pharmacological agents has not demonstrated better efficacy and has led to increased side effects. High rate repetitive transcranial magnetic stimulation (rTMS) has been reported to be effective in episodic migraine and can convert CM to episodic migraine. A combination of high rate rTMS with a pharmacological agent may be more effective compared to rTMS alone.

- **Objectives**: We evaluate the efficacy and safety of 10 Hz rTMS compared to rTMS and amitriptyline in CM.

- **Study design**: Randomized controlled trial.

- **Setting**: Tertiary care teaching institute in India.

- **Methods**: Patients with CM, as per the International Classification of Headache Disorder third edition (ICHD-3) beta criteria, were included if their ages were between 18 and 55 years. CM was defined as having 15 headache days per month, with at least 8 of these attacks having migraine characteristics for a period of more than 3 months. Patients with major psychiatric, other neurological or systemic diseases, and those on migraine prophylaxis were excluded. The demographic details, frequency of headache attacks and headache days per month, migraine triggers, and associated symptoms were noted. The severity of headache was noted using a 0–10 Visual Analog Scale, and the number of abortive drugs per month was recorded. CM patients were randomly assigned to rTMS (group I) or rTMS and amitriptyline (group II).

---

### Amitriptyline for neuropathic pain in adults [^113ymtNU]. The Cochrane Database of Systematic Reviews (2015). High credibility.

This is an updated version of the original Cochrane review published in Issue 12, 2012. That review considered both fibromyalgia and neuropathic pain, but the effects of amitriptyline for fibromyalgia are now dealt with in a separate review. Amitriptyline is a tricyclic antidepressant that is widely used to treat chronic neuropathic pain (pain due to nerve damage). It is recommended as a first-line treatment in many guidelines. Neuropathic pain can be treated with antidepressant drugs in doses below those at which the drugs act as antidepressants.

- **Objectives**: To assess the analgesic efficacy of amitriptyline for relief of chronic neuropathic pain and the adverse events associated with its use in clinical trials.

- **Search methods**: We searched CENTRAL, MEDLINE, and EMBASE to March 2015, together with two clinical trial registries and the reference lists of retrieved papers, previous systematic reviews, and other reviews. We also used our own hand-searched database for older studies.

- **Selection criteria**: We included randomized, double-blind studies of at least four weeks' duration comparing amitriptyline with placebo or another active treatment in chronic neuropathic pain conditions.

- **Data collection and analysis**: We performed analysis using three tiers of evidence. First tier evidence derived from data meeting best standards and subject to minimal risk of bias (outcome equivalent to substantial pain intensity reduction, intention-to-treat analysis without imputation for dropouts; at least 200 participants in the comparison, 8 to 12 weeks' duration, parallel design).

---

### Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society [^112b6LRE]. Neurology (2019). High credibility.

Regarding specific circumstances for migraine, particularly with respect to pediatric and adolescent patients in pharmacologic prophylaxis, the AAN/AHS 2019 guidelines recommend counseling patients of childbearing potential about the potential of topiramate to decrease the efficacy of oral combined hormonal contraceptives, especially at doses greater than 200 mg daily, when offering topiramate for migraine prevention. Patients of childbearing potential should discuss optimal contraception methods with their healthcare provider during treatment when being offered topiramate or valproate for migraine prevention.

---

### A comparative study on prophylactic efficacy of cinnarizine and amitriptyline in childhood migraine: a randomized double-blind clinical trial [^116t5PKf]. Cephalalgia (2024). High credibility.

Pediatric migraine prophylaxis is indicated when headaches are frequent and/or disabling. We aimed to conduct a study to compare the efficacy of cinnarizine and amitriptyline in pediatric migraine prophylaxis.

- **Methods**: In a randomized, double-blind trial, patients aged 4–17 years with migraine who were eligible for prophylaxis were enrolled. The primary outcome was a reduction response rate of ≥ 50% with p < 0.005. No serious adverse events were observed.

- **Conclusions**: Both medications are effective in ameliorating migraine headaches and related disabilities. However, amitriptyline appears to be a preferable option over cinnarizine, given its faster onset of action, efficacy in reducing headache duration, and longer-lasting effects.

---

### Eletriptan for acute migraine headaches in adults [^114cFXTm]. The Cochrane Database of Systematic Reviews (2010). Low credibility.

The protocol for this review does not include an abstract. The primary objective is to determine the efficacy and tolerability of eletriptan compared to placebo and other active interventions for treating acute migraine headaches in adults.

---

### Two different doses of amitriptyline ER in the prophylaxis of migraine: Long-term results and predictive factors [^113gmNXv]. European Journal of Neurology (2009). Low credibility.

The rationale for our study was to examine the prophylactic benefit of two doses of amitriptyline over a 6-month observational period in patients with migraine. We aimed to evaluate whether 50 mg of amitriptyline extended release was more effective than 25 mg in reducing the number of migraine days.

- **Methods**: The primary outcome measure was the reduction of migraine days over time, i.e. 3 and 6 months after patient enrollment. As secondary analyses, predictors of treatment response were evaluated. Treatment response was defined as a reduction of ≥ 30% and ≥ 50% in migraine headache days over time.

- **Results**: The intent-to-treat population comprised 132 patients (female 96; male 36) with migraine. Median migraine days per month were reduced from 7 days (range: 6–15) at baseline, to 6 days (range: 4–12); P included or ≥ 30% and response rate ≥ 50% at 6 months.

- **Conclusions**: The prophylactic effect of amitriptyline observed in our study was rather weak and did not differ between the two treatment groups. The results of this 6-month, prospective, open-label clinical observation are therefore not encouraging.

---

### EFNS guideline on the drug treatment of migraine — revised report of an EFNS task force [^116qdqh7]. European Journal of Neurology (2009). High credibility.

Regarding preventative measures for migraine, specifically in terms of migraine prophylaxis, the EFNS 2009 guidelines recommend offering amitriptyline 50–150 mg or venlafaxine 75–150 mg as a second choice for migraine prophylaxis.

---

### Suppression of cortical spreading depression in migraine prophylaxis [^112mnQ6S]. Annals of Neurology (2006). Low credibility.

Topiramate, valproate, propranolol, amitriptyline, and methysergide have been widely prescribed for migraine prophylaxis, but their mechanism or site of action is uncertain. Cortical spreading depression (CSD) has been implicated in migraine and as a headache trigger, and can be evoked in experimental animals by electrical or chemical stimulation. We hypothesized that migraine prophylactic agents suppress CSD as a common mechanism of action.

- **Methods**: Rats were treated either acutely or chronically over weeks and months, with one of the above migraine prophylactic drugs, vehicle, or D-propranolol, a clinically ineffective drug. The impact of treatment was determined on the frequency of evoked CSDs after topical potassium application or on the incremental cathodal stimulation threshold to evoke CSD.

- **Results**: Chronic daily administration of migraine prophylactic drugs dose-dependently suppressed CSD frequency by 40 to 80% and increased the cathodal stimulation threshold, whereas acute treatment was ineffective. Longer treatment durations produced stronger CSD suppression. Chronic D-propranolol treatment did not differ from saline control.

- **Interpretation**: Our data suggest that CSD provides a common therapeutic target for widely prescribed migraine prophylactic drugs. Assessing CSD threshold may prove useful for developing new prophylactic drugs and improving upon existing ones.

---

### Migraine: Preventive treatment [^1114kAYC]. Cephalalgia (2002). Low credibility.

Migraine is a common episodic headache disorder. A comprehensive headache treatment plan includes acute attack treatment to relieve pain and impairment and long-term preventive therapy to reduce attack frequency, severity, and duration. Circumstances that might warrant preventive treatment include: (i) migraine that significantly interferes with the patient's daily routine despite acute treatment; (ii) failure, contraindication to, or troublesome side-effects from acute medications; (iii) overuse of acute medications; (iv) special circumstances, such as hemiplegic migraine; (v) very frequent headaches (more than two a week); or (vi) patient preference.

Start the drug at a low dose. Give each treatment an adequate trial. Avoid interfering, overused, and contraindicated drugs. Re-evaluate therapy. Ensure that a woman of childbearing potential is aware of any potential risks. Involve patients in their care to maximize compliance. Consider co-morbidity. Choose a drug based on its proven efficacy, the patient's preferences and headache profile, the drug's side-effects, and the presence or absence of coexisting or co-morbid disease.

Drugs that have documented high efficacy and mild to moderate adverse events (AEs) include beta-blockers, amitriptyline, and divalproex. Drugs with lower documented efficacy and mild to moderate AEs include selective serotonin reuptake inhibitors (SSRIs), calcium channel antagonists, gabapentin, topiramate, riboflavin, and non-steroidal anti-inflammatory drugs.

---

### Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of migraine in adults [^117GAc8k]. The Cochrane Database of Systematic Reviews (2015). High credibility.

This is an updated version of the original Cochrane review published in 2005 on selective serotonin reuptake inhibitors (SSRIs) for preventing migraine and tension-type headache. The original review has been split into two parts, and this review now solely addresses migraine prevention. Another updated review is under development to cover tension-type headache. Migraine is a common disorder. The chronic forms are associated with disability and have a high economic impact. In light of discoveries about the role of serotonin and other neurotransmitters in pain mechanisms, selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) have been evaluated for migraine prevention.

- **Objectives**: To determine the efficacy and tolerability of SSRIs and SNRIs compared to placebo and other active interventions in the prevention of episodic and chronic migraine in adults.

- **Search methods**: For the original review, we searched MEDLINE (1966 to January 2004), EMBASE (1994 to May 2003), the Cochrane Central Register of Controlled Trials (CENTRAL 2003, Issue 4), and Headache Quarterly (1990 to 2003). For this update, we applied a revised search strategy to reflect the broader type of intervention (SSRIs and SNRIs). We searched CENTRAL (2014, Issue 10), MEDLINE (1946 to November 2014), EMBASE (1980 to November 2014), and PsycINFO (1987 to November 2014). We also checked the reference lists of retrieved articles and searched trial registries for ongoing trials.

We included randomized controlled trials comparing SSRIs or…

---

### EFNS guideline on the drug treatment of migraine — revised report of an EFNS task force [^116rXaZ8]. European Journal of Neurology (2009). High credibility.

Regarding medical management for migraine, more specifically with respect to the management of acute attacks, the EFNS 2009 guidelines recommend offering the following triptans for acute management of patients with migraine attacks:

- **Sumatriptan**: 25–100 mg PO, including rapid-release; 25 mg suppository; 10–20 mg intranasal; or 6 mg SC.

- **Zolmitriptan**: 2.5–5 mg PO, including disintegrating form; or 2.5–5 mg intranasal.

- **Naratriptan**: 2.5 mg PO.

- **Rizatriptan**: 10 mg PO.

- **Almotriptan**: 12.5 mg PO.

- **Eletriptan**: 20–40 mg PO.

- **Frovatriptan**: 2.5 mg PO.

---

### Trial of amitriptyline, topiramate, and placebo for pediatric migraine [^116Xp3wV]. The New England Journal of Medicine (2017). Low credibility.

Which medication, if any, to use to prevent the headache of pediatric migraine has not been established.

- **Methods**: We conducted a randomized, double-blind, placebo-controlled trial of amitriptyline (1 mg per kilogram of body weight per day), topiramate (2 mg per kilogram per day), and placebo in children and adolescents 8 to 17 years of age with migraine. Patients were randomly assigned in a 2:2:1 ratio to receive one of the medications or placebo. The primary outcome was a relative reduction of 50% or more in the number of headache days in the comparison of the 28-day baseline period with the last 28 days of a 24-week trial. Secondary outcomes were headache-related disability, headache days, number of trial completers, and serious adverse events that emerged during treatment.

- **Results**: A total of 361 patients underwent randomization, and 328 were included in the primary efficacy analysis (132 in the amitriptyline group, 130 in the topiramate group, and 66 in the placebo group). The trial was concluded early for futility following a planned interim analysis. There were no significant between-group differences in the primary outcome, which occurred in 52% of the patients in the amitriptyline group, 55% of those in the topiramate group, and 61% of those in the placebo group (amitriptyline vs. placebo, P = 0.26; topiramate vs. placebo, P = 0.48; amitriptyline vs. topiramate, P = 0.49). There were also no significant between-group differences in headache-related disability, headache days, or the percentage of patients who completed the 24-week treatment period.

---

### Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society [^111ZpTG6]. Neurology (2012). High credibility.

Regarding preventative measures for migraines, more specifically concerning migraine prophylaxis, the AAN 2012 guidelines recommend offering amitriptyline or venlafaxine as a second choice for migraine prophylaxis.

---

### SIGN 155 pharmacological management of migraine: A national clinical guideline [^117Eu8tw]. SIGN (2023). High credibility.

Regarding the medical management of migraine, particularly in the context of acute attacks, the SIGN 2023 guidelines recommend offering triptans (sumatriptan 50–100 mg, or other triptans if sumatriptan fails) as first-line therapy for patients with acute migraine.

---

### Randomised clinical trial comparing melatonin 3 mg, amitriptyline 25 mg and placebo for migraine prevention [^112352Qk]. Journal of Neurology, Neurosurgery, and Psychiatry (2016). Low credibility.

The study assessed patients suffering from migraine, who were eligible if they met specific inclusion criteria: aged between 18–65 years, had experienced migraine with or without aura for at least one year as per the International Classification of Headache Disorders, third edition, β-version, with onset before the age of 50. Additionally, participants needed to have at least three migraine headache attacks or four migraine headache days per month — defined as any occurrence of migraine headache pain lasting at least 30 minutes requiring acute treatment. They could also present with migraine or non-migraine headache attacks for 10 days per month, or have simple analgesic intake for over 15 days per month for more than three months.

In terms of current treatments, patients were either using preventive medications such as β-blockers, tricyclic antidepressants, calcium channel blockers, antiepileptic drugs, bupropion, or serotonergic norepinephrine reuptake inhibitors and were unable to discontinue these treatments. Patients who had previously taken melatonin, amitriptyline, or agomelatine, or had uncontrolled hypertension (sitting systolic blood pressure > 160 mm Hg or sitting diastolic blood pressure > 90 mm Hg) at the screening visit or at randomization were also included. Data collection was conducted after these criteria were verified.

---

### Migraine headache prophylaxis [^117AURMY]. American Family Physician (2025). High credibility.

Regarding preventive measures for migraines, particularly concerning migraine prophylaxis, the AAFP 2025 guidelines recommend offering CGRP inhibitors as a first-line option.